Literature DB >> 22171680

Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness.

R Sinclair1, M Patel, T L Dawson, A Yazdabadi, L Yip, A Perez, N W Rufaut.   

Abstract

Androgenetic alopecia affects both men and women. In men it produces male pattern hair loss with bitemporal recession and vertex baldness. In women it produces female pattern hair loss (FPHL) with diffuse alopecia over the mid-frontal scalp. FPHL occurs as a result of nonuniform hair follicle miniaturization within follicular units. Diffuse alopecia is produced by a reduction in the number of terminal fibres per follicular unit. Baldness occurs only when all hairs within the follicular units are miniaturized and is a relatively late event in women. The concepts of follicular units and primary and secondary hair follicles within follicular units are well established in comparative mammalian studies, particularly in sheep. However, discovery of these structures in the human scalp hair and investigation of the changes in follicular unit anatomy during the development of androgenetic alopecia have provided a clearer understanding of the early stages of androgenetic alopecia and how the male and female patterns of hair loss are related. FPHL is the most common cause of alopecia in women and approximately one-third of adult caucasian women experience hair loss. The impact of FPHL is predominantly psychological. While men anticipate age-related hair loss, hair loss in women is usually unexpected and unwelcome at any age. Treatment options to arrest hair loss progression and stimulate partial hair regrowth for FPHL include the androgen receptor antagonists spironolactone and cyproterone acetate, the 5α-reductase inhibitor finasteride and the androgen-independent hair growth stimulator minoxidil. These treatments appear to work best when initiated early. Hair transplantation should be considered in advanced FPHL that is resistant to medical treatments. Hair transplantation requires well-preserved hair growth over the occipital donor area. The psychological impact of FPHL may also be reduced by cosmetic products that improve the appearance of the hair. These agents work to minimize hair fibre breakage, improve hair volume or conceal visible bald scalp.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22171680     DOI: 10.1111/j.1365-2133.2011.10630.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

Review 1.  Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.

Authors:  Selma F Witchel; Sergio E Recabarren; Frank González; Evanthia Diamanti-Kandarakis; Kai I Cheang; Antoni J Duleba; Richard S Legro; Roy Homburg; Renato Pasquali; Rogerio A Lobo; Christos C Zouboulis; Fahrettin Kelestimur; Franca Fruzzetti; Walter Futterweit; Robert J Norman; David H Abbott
Journal:  Endocrine       Date:  2012-06-04       Impact factor: 3.633

2.  The XPB Subunit of the TFIIH Complex Plays a Critical Role in HIV-1 Transcription and XPB Inhibition by Spironolactone Prevents HIV-1 Reactivation from Latency.

Authors:  Luisa Mori; Katharine Jenike; Yang-Hui Jimmy Yeh; Benoît Lacombe; Chuan Li; Adam Getzler; Sonia Mediouni; Michael Cameron; Matthew Pipkin; Ya-Chi Ho; Bertha Cecilia Ramirez; Susana Valente
Journal:  J Virol       Date:  2020-11-25       Impact factor: 5.103

3.  [Spironolactone in dermatological treatment. On and off label indications].

Authors:  C M Salavastru; K Fritz; G S Tiplica
Journal:  Hautarzt       Date:  2013-10       Impact factor: 0.751

Review 4.  Cure and Long-Term Remission Strategies.

Authors:  Luisa Mori; Susana T Valente
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Regulation of signaling pathways in hair follicle stem cells.

Authors:  Xiaoxiang Wang; Yinghui Liu; Jia He; Jingru Wang; Xiaodong Chen; Ronghua Yang
Journal:  Burns Trauma       Date:  2022-07-04

6.  A Randomized, Double-blind, Placebo-controlled, Multi-center, Extension Trial Evaluating the Efficacy of a New Oral Supplement in Women with Self-perceived Thinning Hair.

Authors:  Glynis Ablon; Steven Dayan
Journal:  J Clin Aesthet Dermatol       Date:  2015-12

7.  Alopecia with endocrine therapies in patients with cancer.

Authors:  Vishal Saggar; Shenhong Wu; Maura N Dickler; Mario E Lacouture
Journal:  Oncologist       Date:  2013-09-13

Review 8.  Interventions for female pattern hair loss.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Jan Schoones
Journal:  Cochrane Database Syst Rev       Date:  2016-05-26

9.  [Drug treatment of alopecia].

Authors:  H Wolff
Journal:  Internist (Berl)       Date:  2015-10       Impact factor: 0.743

Review 10.  Platelet Rich Plasma Hybridized Adipose Transplant (PHAT) for the Treatment of Hair Loss: A Case Series.

Authors:  Benjamin Talei; Orr Shauly; Daniel Gould
Journal:  Aesthetic Plast Surg       Date:  2021-07-08       Impact factor: 2.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.